American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 412-424 , September 2008

Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

  • Mahboob Rahman, MD, MS

      Affiliations

    • Case Western Reserve University, University Hospitals of Cleveland Case Medical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, OH
    • ,
  • Charles Baimbridge, MS

      Affiliations

    • University of Texas School of Public Health, Houston, TX
    • ,
  • Barry R. Davis, MD, PhD

      Affiliations

    • University of Texas School of Public Health, Houston, TX
    • ,
  • Joshua Barzilay, MD

      Affiliations

    • Kaiser Permanente of Georgia, Tucker, GA
    • ,
  • Jan N. Basile, MD

      Affiliations

    • VAMC Charleston, Charleston, SC
    • ,
  • Mario A. Henriquez, MD

      Affiliations

    • Bronx Nephrology Hypertension, Bronx, NY
    • ,
  • Anne Huml, MD

      Affiliations

    • Case Western Reserve University, University Hospitals of Cleveland Case Medical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, OH
    • ,
  • Nelson Kopyt, DO

      Affiliations

    • Lehigh Valley Hospital, Allentown, PA
    • ,
  • Gail T. Louis, RN

      Affiliations

    • Tulane University Health Sciences Center, New Orleans, LA
    • ,
  • Sara L. Pressel, MS

      Affiliations

    • University of Texas School of Public Health, Houston, TX
    • Corresponding Author InformationAddress correspondence to Sara L. Pressel, MS, 1200 Herman Pressler St, Ste E801, Houston, TX 77030
    • ,
  • Clive Rosendorff, MD, PhD

      Affiliations

    • Mount Sinai School of Medicine, New York
    • James J. Peters VA Medical Center, Bronx, NY
    • ,
  • Sithiporn Sastrasinh, MD

      Affiliations

    • VA New Jersey Health Care System, East Orange, NJ
    • ,
  • Carol Stanford, MD

      Affiliations

    • University of Missouri School of Medicine, Kansas City, MO
    • ,
  • ALLHAT Collaborative Research Group

Received 6 December 2007 ,Accepted 12 May 2008.

References 

  1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(1):S1–S266
  2. Kaysen GA. Dyslipidemia in chronic kidney disease: Causes and consequences. Kidney Int Suppl. 2006;104:S55–S58
  3. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26:670–675
  4. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–2091
  5. Kosch M, Barenbrock M, Suwelack B, Schaefer RM, Rahn KH, Hausberg M. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme A reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am J Kidney Dis. 2003;41:1088–1096
  6. Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant. 2006;21:337–344
  7. Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?. J Am Soc Nephrol. 2005;16(suppl 1):S11–S17
  8. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–570
  9. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002;40:67–73
  10. Thomas ME, Harris KP, Ramaswamy C, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int. 1993;44:1124–1129
  11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007
  12. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–946
  13. Levey AS, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:0828A;(abstr)
  14. Grambsch P, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrica. 1994;81:515–526
  15. Klein JP, Moeschberger ML. Survival Analysis—Techniques for Censored and Truncated Data. (ed 2). New York, NY: Springer-Verlag; 2003;
  16. Singer JD, Willet JB. Applied Longitudinal Data Analysis. New York, NY: Oxford University; 2003;
  17. Agarwal R. Effects of statins on renal function. Am J Cardiol. 2006;97:748–755
  18. Atthobari J, Brantsma AH, Gansevoort RT, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant. 2006;21:3106–3114
  19. Feringa HH, Karagiannis SE, Chonchol M, et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol. 2007;18:1872–1879
  20. Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35:447–451
  21. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant. 2002;17:798–802
  22. Nielsen S, Schmitz O, Moller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1993;36:1079–1086
  23. Rayner BL, Byrne MJ, van Zyl SR. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol. 1996;46:219–224
  24. Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997;20:1891–1895
  25. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease (A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study). J Clin Pathol. 2004;57:728–734
  26. Imai Y, Suzuki H, Saito T, Tsuji I, Abe K, Saruta T. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia (Pravastatin and Renal Function Research Group). Clin Exp Hypertens. 1999;21:1345–1355
  27. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia. 1995;38:604–609
  28. Gheith OA, Sobh MA, Mohamed K, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron. 2002;91:612–619
  29. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605–1613
  30. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–178
  31. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  32. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645–651
  33. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–732
  34. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563
  35. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med. 2006;145:117–124
  36. Tiwari A. An overview of statin-associated proteinuria. Drug Discov Today. 2006;11:458–464
  37. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;84:S207–S210

 Originally published online as doi:10.1053/j.ajkd.2008.05.027 on August 6, 2008.

 Trial registration: www.clinicaltrials.gov; study number: NCT00000542.

PII: S0272-6386(08)00999-2

doi: 10.1053/j.ajkd.2008.05.027

American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 412-424 , September 2008

Article Tools

* Image Usage & Resolution